Lioresal should be administered to end stage renal failure patients only if the expected benefit
outweighs the potential risk. These patients should be closely monitored for prompt diagnosis
of early signs and/or symptoms of toxicity (e.g. somnolence, lethargy) (see
“PRECAUTIONS” and “OVERDOSAGE”).